What happens when you take phenobarbital with vitamin D?
Phenobarbital is one of the oldest anticonvulsants in continuous clinical use — first introduced in 1912 — and it remains widely used worldwide for generalized tonic-clonic and focal seizures, status epilepticus, and neonatal seizures. It is also one of the strongest inducers of hepatic cytochrome P450 enzymes in the entire pharmacopoeia, which sets up a particularly aggressive interaction with vitamin D.
Phenobarbital affects vitamin D through two distinct mechanisms. First, it activates two nuclear receptors — the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) — which together upregulate transcription of CYP3A4 and CYP24A1, the enzymes that catabolize 25-hydroxyvitamin D (calcidiol) and 1,25-dihydroxyvitamin D (calcitriol) into inactive metabolites. Healthy volunteers given enzyme inducers for as little as two weeks have shown serum 25(OH)D drops of up to 70 percent.
Second, and more uniquely, phenobarbital has been shown to directly suppress the expression of CYP27A1 and CYP2D25 — the very hepatic enzymes that perform the initial 25-hydroxylation step that converts dietary or skin-synthesized vitamin D3 into 25(OH)D. So phenobarbital both speeds the destruction of vitamin D and slows its activation. This dual action helps explain why phenobarbital users frequently have lower 25(OH)D than patients on other enzyme-inducing anticonvulsants matched for therapy duration.
The downstream cascade then follows the same pattern as other anticonvulsant-induced osteomalacia: low 25(OH)D leads to reduced intestinal calcium absorption, low or low-normal serum calcium, compensatory rise in parathyroid hormone, increased bone turnover, and progressive loss of bone mineral density.
Why is this important?
Phenobarbital-induced bone disease is a recognized clinical entity dating back to the 1960s and 1970s, and it is documented to be more severe than with most other anticonvulsants because of phenobarbital's potency as an enzyme inducer plus the direct suppression of 25-hydroxylase. Studies in long-term phenobarbital users have shown low 25(OH)D in the majority of patients and frank osteomalacia in a substantial minority, with adults reporting bone pain, proximal muscle weakness, and an elevated fracture rate.
Pediatric patients are at particularly high risk. Phenobarbital is still used in infants and young children for febrile and other seizures in many parts of the world, and growing bones are vulnerable to deficient vitamin D and calcium. Pediatric rickets has been reported in children on long-term phenobarbital.
Phenobarbital is also commonly used in older adults — including in hospice and palliative settings — and in people who are institutionalized or have limited sun exposure, all of whom already have higher baseline risk for vitamin D deficiency.
What should you do?
If you or someone you care for is on long-term phenobarbital, ask the prescriber for a baseline 25-hydroxyvitamin D, calcium, phosphate, alkaline phosphatase, and ideally PTH. Repeat these labs at least annually, and more often if 25(OH)D is already low.
Most long-term phenobarbital users will need supplemental vitamin D3 (cholecalciferol), typically 1,000 to 2,000 IU per day for maintenance, with higher loading doses (e.g., 50,000 IU weekly for 8 to 12 weeks) often required if levels are already deficient. Pair vitamin D supplementation with adequate calcium intake (around 1,000 to 1,200 mg per day from food and supplements combined) and weight-bearing exercise where feasible.
For children on phenobarbital, work with the pediatric neurologist and possibly a pediatric endocrinologist or bone specialist; pediatric dosing of vitamin D3 differs and depends on age and baseline status. Track vitamin D doses, sun exposure, and any bone or muscle symptoms in Pilora.
Do not stop phenobarbital without medical guidance — abrupt discontinuation can precipitate seizures or severe withdrawal in long-term users.
Which specific products are affected?
The interaction applies to phenobarbital (Luminal, Solfoton, generic phenobarbital, and combination products like Donnatal which contains phenobarbital plus belladonna alkaloids) and to primidone (Mysoline), which is partially metabolized to phenobarbital. The same mechanism — enzyme induction and depletion of 25(OH)D — applies in similar magnitude to phenytoin and carbamazepine, and to a somewhat lesser extent to oxcarbazepine and topiramate. Newer non-inducing anticonvulsants like levetiracetam and lamotrigine are not associated with the same degree of vitamin D depletion.
On the supplement side, vitamin D3 (cholecalciferol) is preferred over vitamin D2 (ergocalciferol) for routine repletion in this context. Activated forms (calcitriol, alfacalcidol) are sometimes used in refractory anticonvulsant-induced osteomalacia under specialist supervision because they bypass the hepatic hydroxylation step that phenobarbital interferes with — but they carry a higher risk of hypercalcemia and require closer monitoring.
The bottom line
Phenobarbital depletes vitamin D especially aggressively because it both accelerates catabolism of 25(OH)D through CYP induction and directly suppresses the 25-hydroxylase enzyme that creates 25(OH)D in the first place. Long-term users — particularly children and older or institutionalized adults — should have 25(OH)D monitored at least annually and almost always need vitamin D3 supplementation (commonly 1,000 to 2,000 IU per day) plus adequate calcium intake to protect bone health.